arrow
M

Mehdi Brahmi

centre leon berard
H指数:28
被引数:2,795

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Descriptive Analysis of Epidemiology, Demographic Characteristics, and Survival of Dedifferentiated Liposarcoma in France

法国去分化脂肪肉瘤的流行病学、人口统计学特征及生存描述性分析

2026-11-030
OAAI
Myxoid neoplasms with MAP3K kinase fusion: a study of 39 cases

黏液样肿瘤伴MAP3K激酶融合:39例研究

2026-08-190
PRE
Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial

对于新诊断的多发性转移性尤因肉瘤患者,采用序贯多模式治疗方法的临床价值:法国前瞻性CombinaiR3 II期试验结果

2025-11-170
PRE
Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life national setting over a decade

转移性骨肉瘤,真实世界国家背景下一十年来患者的治疗模式与结局

2025-09-280
PRE
Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study

与免疫检查点抑制剂应答相关的临床和生物学因素:晚期肉瘤的IMPRESARC研究——一项法国回顾性多中心队列研究

Cancer
IF5.1
2025-09-050
OAAI
Sinonasal Sarcomas Management: An International Consensus Statement

鼻腔鼻窦肉瘤的管理:一项国际共识声明

2025-09-010
OAAI
Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry

临床表现、治疗管理及结局:11,132例脂肪肉瘤患者的流行病学研究(基于NETSARC+登记系统)

2025-07-310
PREAI
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial☆

瑞戈非尼作为一线多柔比星类化疗后的维持疗法在进展期非脂肪源性软组织肉瘤患者中的应用:一项双盲随机试验☆

2025-04-080
PRE
Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC

神经纤维瘤病1型(NF1)相关胃肠道间质瘤(GISTs)的临床描述及预后评分的开发:一项来自NETSARC的回顾性研究

2025-03-010
OAAI
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

6年与3年伊马替尼辅助治疗局部GIST复发风险高的患者的随机研究

2024-12-016
OAAI
Role of 18F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?
2024-10-080
PRE
LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib

LENVAGIST:一项多中心、比较性、安慰剂(P)对照、双盲、II期研究,旨在评估在伊马替尼和舒尼替尼治疗失败的晚期GIST患者中伦伐替尼(L)的疗效。

2024-09-010
PRE
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
2024-09-010
PRE